SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand

Acta Tropica

Volumn 67, Issue 3, 1997, Pages 215-227

  Migasena, S ^a   Heppner, D G ^b,c   Kyle, D E ^b   Chongsuphajaisiddhi, T ^a   Gordon, D M ^c   Suntharasamai, P ^a   Permpanich, B ^b   Brockman, A ^d   Pitiuttutham, P ^a   Wongsrichanalai, C ^b   Srisuriya, P ^a   Phonrat, B ^a   Pavanand, K ^b   Viravan, C ^a   Ballou, W R ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

Malaria naive adults; Plasmodium falciparum; SPf66 malaria vaccine

Indexed keywords

MALARIA VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION CONTROL; INJECTION SITE; MALARIA; MALE; PHASE 1 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THAILAND; VACCINATION;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALARIA; MALARIA VACCINES; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SEX CHARACTERISTICS; THAILAND; VACCINES, SYNTHETIC;

PLASMODIUM FALCIPARUM;

EID: 17444444396     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(97)00061-2     Document Type: Article

References (29)

1. Alonso, P.L., Smith, T., Armstrong Schellenberg, J.R.M., Masanja, H., Mwankusye, S., Urassa, H., Bastos de Azevedo, I., Chongela, J., Kobero, S., Menendez, C., Hurt, N., Thomas, M.C., Lyimo, E., Weiss, N.A., Hayes, R., Kitua, A.Y., Lopez, M.C., Kilama, W.L., Teuscher, T., Tanner, M., 1994. Randomised trial of efficacy of SPf66 vaccine againt Plasmodium falciparum malaria in children in southern Tanzania. Lancet 34, 1175-1181.
2. Amador, R., Moreno, A., Murillo, L.A., Sierra, O., Saavedra, D., Rojas, M., Mora, A.L., Rocha, C.L., Alvarado, F., Falla, J.C., Orozco, M., Coronell, C., Ortega, N., Molano, A., Velasquez, J.F., Valero, M.V., Franco, L., Guzman, F., Salazar, L.M., Espejo, F., Mora, E., Farfan, R., Zapata, N., Rosas, J., Calvo, J.C., Castro, J., Quinones, T., Nunez, F., Patarroyo, M.E., 1992. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J. Infect. Dis. 10, 179-184.
3. Ballou, W.R., Blood, J., Chongsuphajaisiddhi, T., Gordon, D.M., Heppner, D.G., Kyle, D.E., Luxemburger, C., Nosten, F., Sadoff, J.C., Singhasivanon, P., White, N.J., Webster, H.K., Wittes, J., Wongsrichanalai, C., 1995. Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a Phase lib efficacy study. Parasitology 110, S25-S36.
4. Beck, H.P., Felger, I., Barker, M., Bugawan, T., Genton, B., Alexander, N., Jazwinska, E., Erlich, H., Alpers, M., 1995. Evidence of HLA class II association with antibody respones against the malaria vaccine SPf66 in a naturally exposed population. Am. J. Trop. Med. Hyg. 53, 284-288.
5. D'Alessandro, U., Leach, A., Drakeley, C.J., Bennett, S., Olaleye, B.O., Fegan, G.W., Jawara, M., Langerock, P., George, M.O., Targett, G.A.T., Greenwood, B.M., 1995. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346, 462-467.
6. Goilav, C., Zuckerman, J., Lafrenz, M., Vidor, E., Lauwers, S., Ratheau, C., Benichou, G., Zuckerman, A., 1995. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J. Med. Virol. 46, 287-292.
7. Gordon, D.M., Duffy, P.E., Heppner, D.G., Lyon, J.A., Williams, J.A., Scheumann, D., Farleigh, L., Stacey, D., Haynes, J.D., Sadoff, J.C., Ballou, W.R., 1996. Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the US. Am. J. Trop. Med. Hyg. 55, 63-68.
8. Green, M.S., Shohat, T., Lerman, Y., Cohen, D., Slepon, R., Duvdevani, O., Varsono, N., Dagan, R., Mendelson, E., 1994. Sex differences in the humoral antibody response in young adults. Int. J. Epidemiol. 23, 1078-1081.
9. Leach, A., Drakeley, C.J., D'Alesandro, U., Fegan, G.W., Bennett, S., Ballou, W.R., Targett, G.A.T., Greenwood, B.M., 1995. A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants. Parasite Immunol. 17, 441-444.
10. Lopez, M.C., Silva, Y., Thomas, M.C., Garcia, A., Faus, M.J., Alonso, P., Martinez, F., Del Real, G., Alonso, C., 1994. Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine. Vaccine 12, 585-591.
11. Millet, P., Campbell, G.H., Sulzer, A.J., Grady, K.K., Pohl, J., Aikawa, M., Collins, W.E., 1993. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66. Am. J. Trop. Med. Hyg. 48, 424-431.
12. Murillo, L.A., Tenjo, F.A., Clavijo, O.P., Orozco, M., Sampaio, S., Kalil, J., Patarroyo, M.E., 1992. A specific T-cell receptor genotype in the immune response to a synthetic Plasmodium falciparum malaria vaccine. Parasite Immunol. 14, 87-94.
13. Nosten, F., Luxemburger, C., Kyle, D.E., Gordon, D.M., Ballou, W.R., Sadoff, J.C., Brockman, A., Permpanich, P., Chongsuphajaisiddhi, T., Heppner, D.G., 1997. Phase I trial of the SPF66 malaria vaccine in a malaria experienced population in Southeast Asia. Am. J. Trop. Med. Hyg., in press.
14. Nosten, F., Luxemburger, C., Kyle, D.E., Ballou, W.R., Wittes, J., Wah, E., Chongsuphajaisiddhi, T., Gordon, D.M., White, N.J., Sadoff, J.C., Heppner, D.G., 1996. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 348, 701-707.
15. Noya, O., Berti, Y.G., Alarcon de Noya, B., Borges, R., Zerpa, N., Urbaez, J.D., Madonna, A., Garrido, E., Jimenez, M.A., Borges, R.E., Garcia, P., Reyes, I., Prieto, W., Colmenares, C., Pabon, R., Barraez, T., de Caceres, L.G., Godoy, N., Sifontes, R., 1994. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J. Infect. Dis. 170, 396-402.
16. Oliveria, P.M., Silva, A.E., Kemp, V.L., Juliano, Y., Ferraz, M.L., 1995. Comparison of three different schedules of vaccination against hepatitis B in health care workers. Vaccine 13, 791-794.
17. Patarroyo, M.E., Romero, P., Torres, M.L., Clavijo, P., Moreno, A., Martinez, A., Rodriquez, R., Guzman, F., Cabezas, E., 1987. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328, 629-632.
18. Patarroyo, M.E., Amador, R., Clavijo, P., Moreno, A., Guzman, F., Romero, P., Tascon, R., Franco, A., Murillo, L.A., Ponton, G., Trujillo, G., 1988. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332, 158-161.
19. Patarroyo, G., Franco, L., Amador, R., Murillo, L.A., Rocha, C.L., Rojas, M., Patarroyo, M.E., 1992. Study of the safety and immunogenicity of the synthetic malaria vaccine SPf66 in children aged 1-14 years. Vaccine 19, 175-183.
20. Riley, E., 1995. Malaria vaccine trials: SPf66 and all that. Curr. Opin. Immunol. 7, 612-616.
21. Rocha, C.L., Murillo, L.A., Mora, A.L., Rojas, M., Franco, L., Cote, J., Valero, M.V., Moreno, A., Amador, R., Nunez, F., Coronell, C., Patarroyo, M.E., 1992. Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf66. Parasite Immunol. 14, 95-109.
22. Salcedo, M., Barreto, L., Rojas, M., Moya, R., Cote, J., Patarroyo, M.E., 1991. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin. Exp. Immunol. 84, 122-128.
23. Sempertegui, F., Estrell, B., Moscoso, J., Piedrahita, L., Hernandez, D., Gaybor, J., Naranjo, P., Mancero, O., Arias, S., Bernal, R., Cordova, M.E., Suarez, J., Zicker, F., 1994. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 12, 337-342.
24. Struve, J., Aronsson, B., Frenning, B., Granath, F., von Sydow, M., Weiland, O., 1992. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. Scand. J. Infect. Dis. 24, 423-429.
25. Stuerchler, D., 1989. Malaria, how much is there worldwide?. Parasitol. Today 5, 39-40.
26. Teuscher, T., Armstrong Schellenberg, J.R.M., Bastos de Azevedo, I., Hurt, N., Smith, T., Hayes, R., Masanja, H., Silva, Y., Lopez, M.C., Kitua, A., Kilama, W., Tanner, M., Alonso, P.L., 1994. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Vaccine 12, 328-336.
27. Valero, M.V., Amador, L.R., Galindo, C., Figueroa, J., Bello, M.S., Murrillo, L.A., Mora, A.L., Patarroyo, G., Rocha, C.L., Rojas, M., Aponte, J.J., Sarmiento, L.E., Lozada, D.M., Coronell, C.G., Ortega, N.M., Rosas, J.E., Alonso, P.L., Patarroyo, M.E., 1993. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341, 705-710.
28. White, N.J., Nosten, F., 1993. Advances in the chemotherapy and prophylaxis of malaria. Curr. Opin. Infect. Dis. 3, 323-330.
29. Wirtz, R.A., Ballou, W.R., Schneider, I., Chedid, M., Gross, M.J., Young, J.F., Hollingdale, M., Diggs, C.L., Hockmeyer, W., Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp. Parasitol. 63, 166-172.